Wall Street is positive on Can Fite Biopharma ADR Representing 30 Ord Shs (CANF). On average, analysts give CANF a Strong Buy rating. The average price target is $6.5, which means analysts expect the stock to add by 269.32% over the next twelve months.
That average ranking earns CANF an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Can Fite Biopharma ADR Representing 30 Ord Shs Stock Today?
Can Fite Biopharma ADR Representing 30 Ord Shs (CANF) stock is up 2.33% while the S&P 500 is unchanged 0% as of 10:41 AM on Friday, Sep 25. CANF has risen $0.04 from the previous closing price of $1.72 on volume of 40,485 shares. Over the past year the S&P 500 has gained 9.03% while CANF is down -16.59%. CANF earned $0.15 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 11.73.
Click Here to get the full report on Can Fite Biopharma ADR Representing 30 Ord Shs (CANF) Stock.
